Target intelligence / Profile preview

HLA class I histocompatibility antigen, A alpha chain (HLA-A*02) (HLA-A*02)

Target
HLA-A*02
Molecular classification
Receptor, MHC class I molecule, Immunoglobulin superfamily
01

Overview

HLA class I histocompatibility antigen, A alpha chain (specifically the A*02 serotype) is a critical component of the Major Histocompatibility Complex (MHC) class I system, responsible for presenting endogenous peptides to CD8+ cytotoxic T lymphocytes (CTLs) [UniProt: P01892]. It consists of a polymorphic alpha chain non-covalently associated with beta-2 microglobulin, forming a groove that binds peptides derived from intracellular proteins [NCBI Gene: 3105]. This molecule is essential for the immune system to distinguish between self and non-self, as well as for the detection of virally infected or malignant cells. In modern oncology, HLA-A*02 is a primary focus for immunotherapy because it is one of the most prevalent HLA alleles in the Caucasian population, making it a key target for TCR-engineered T-cell therapies and bispecifics like Tebentafusp [FDA: Kimmtrak Label]. These therapies are designed to recognize specific tumor-associated antigens presented by HLA-A*02, such as gp100 or NY-ESO-1 [: NCT03645928]. However, therapeutic efficacy can be limited by tumor-mediated HLA downregulation or the risk of off-target toxicity if the TCR cross-reacts with similar peptides presented on healthy tissues. Furthermore, the high polymorphism of the HLA-A gene necessitates precise patient HLA typing to ensure treatment compatibility.

Other names
HLA-A2MHC class I antigen A*2HLA-A*02:01HLA-A*02Human leukocyte antigen A2
02

Mechanism of action

Presentation of specific intracellular peptides to CD8+ T-cells to initiate immune-mediated cell death; TCR-based therapies and bispecifics bind to the peptide-HLA complex to trigger T-cell activation against target cells [FDA: Kimmtrak Label; ].

03

Biological functions

Antigen presentationImmune responseT-cell activationSelf-nonself recognition
04

Disease associations

CancerInfectionAutoimmune diseaseGraft-versus-host disease
05

Safety considerations

Cytokine release syndrome (CRS)Off-target toxicity due to TCR cross-reactivityTumor immune escape via HLA downregulation
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

HLA-A*02:01 allele statusTumor antigen expressionHLA surface expression levels

Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on HLA class I histocompatibility antigen, A alpha chain (HLA-A*02) (HLA-A*02).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA class I histocompatibility antigen, A alpha chain (HLA-A*02) (HLA-A*02).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call